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Foreword*
This symposium issue is derived from a one-day conference held April 20, 1991, at
Yale University School of Medicine-co-sponsored by the Sections of Hematology
and Medical Oncology, Department ofInternal Medicine, and the Yale Comprehen-
sive Cancer Center. The discussions speak to issues shared by general and subspe-
cialty medicine.
The rapid progress in scientific knowledge and technology in the field ofmedicine
has created many new ethical dilemmas antedating any consensus on older moral
issues. Some ofthese issues are now before the public in referenda, in high-visibility
court cases, and in political debate, most prominently in relation to the costs of and
access to medical care.
Forthose ofuswho did post-medical school training in a university medical center
and remain affiliated with a university or medical research institute, research in
general and clinical research in particular was viewed as an article of faith, as an
unmixed blessing, and above reproach. In "Clinical Trials and Physicians as Double
Agents," Levine highlights conflicts of interest between the physician as researcher
and the physician as trusted healer. Some suggestions are made to protect the
patient's rights and to reduce the extent of the conflict in these dual roles of the
physician.
In his discussion, "Rationing Health Care: Its Impact and Implications for
Hematology-Oncology," Duffy reviews the problems ofmaldistribution and exceed-
ingly high costs of medical care and some of the proposed solutions, including
national health insurance, the Canadian health plan, the Oregon proposal, and
"inter-generational charity" as possible choices for rationing ofmedical care.
The observations on "Cancer Therapy: Reimbursement of New Therapeutic
Technologies" by Williams are based upon his consecutive experiences as clinical
investigator, oncologist in private practice, acting chief of a university section of
medical oncology, clinical oncologist in an oncology group practice, and director of
medical policy for a large health-oriented company. Inevitably, some ofthe concerns
expressed relate to rising health care costs in a period when this nation is either
unwilling or unable to underwrite the cost of providing open-ended access to
available medical technologyfor all itscitizens. Hehighlights someofthe morecostly
and controversial newtherapies, including high-dose chemotherapy for solid tumors,
as well as autologous bone marrow transplantation, hyperthermia for deep-seated
non-cutaneous tumors, autolymphocyte therapy, and colony-stimulating factors. He
provides some criteria for a rational approach to decision making in this perplexing
realm.
Some of the most difficult ethical and legal decision making concerns patients at
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the extremes of life-children and the elderly. Holder considers "Childhood Malig-
nancies and Decision Making" from an attorney'sviewpoint. Shebrings us up to date
on the majorcourt decisions thatpertain toparental refusal ofstandard and research
treatment and the greater freedom of decision of adolescents, who are presumed to
understand the consequences oftheir choices.
In his "Observations on Ethical Problems and Terminal Care," Fischer urges
authors, particularly oftextbooks, to pay more attention to ethical problems and not
to concentrate solely on pathophysiology and pharmacotherapy. He discusses the
principles and origins ofbiomedical ethics and applies them to end-of-life decisions,
and to the management of the persistent vegetative state. He questions the right of
patients to consume unlimited resources when there is no possibility of survival
without heroic and expensive support services that may reduce the care available to
others with treatable conditions and a long-term future of good quality. Finally, he
examines the potential conflict of interest between pharmaceutical companies who
pay physicians/researchers to evaluate their drugs and give substantial gifts to
physicians who prescribe their drugs.
Although the Washington State referendum to amend the law on physician-
assisted termination oflife was narrowly defeated, the issue remains an active one in
other states, includingCalifornia, Michigan, New Hampshire, and Oregon. The issue
of "Euthanasia," particularly voluntary patient-requested euthanasia, is sensitively
reviewed by Brock, an ethicist and not aphysician. Threatening as the subject maybe
to physicians and laymen, it is an option that must be considered to relieve the
physical and emotional suffering ofthose who choose it.
Aside from close family members, no one spends more time with the sick
hospitalized patient than does the nurse. It is the nurse who may become the
patient's confidant andombudsman longbefore thephysician. Hence it is no surprise
that nurses have been in the forefront of patient advocacy and the provision of
compassionate care when cure and meaningful palliation are no longer possible.
Donovan addresses "Nurse Participation in Decisions Regarding Limitation of
Treatment." She derives her perspective from experience as a bedside nurse, clinical
oncology specialist, and teacher.
The symposium ends, appropriately, with a consideration of the final phase of
life-namely, death. Chaplain Mermann has spent the majority of his life as a
practicing physician, a pediatrician, before becoming a minister. He is uniquely
qualified to discuss "Spiritual Aspects of Death and Dying," and points out that
"The physician . . . can make care of the dying more rewarding and fulfilling for all
concerned."
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